COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #72
Source   PDF   Share   Tweet
See all 155 studies
Late treatment study
Arshad et al., Int. J. Infect. Dis., July 1 2020, doi:10.1016/j.ijid.2020.06.099 (Peer Reviewed)
Treatment with Hydroxych loroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19
HC Q decreases mortality from 26.4% to 13.5% (HC Q) or 20.1% (HC Q+AZ). Propensity matched HC Q HR 0.487, p=0.009. Michigan 2,541 patients retrospective. Before propensity matching the HC Q group average age is 5 years younger and the percentage of male patients is 4% higher which is likely to favor the treatment and the control respectively in the before-propensity matching results.
Some reported limtiations of this study are inaccurate [1]. Corticosteroids were controlled for in the multivariate and propensity analyses as were age and comorbidities including cardiac disease and severity of illness. Age was an independent risk factor associated with mortality. HC Q was independently associated with decreased mortality, distinct from the steroid effect. 91% of all patients began treatment within two days of admission. HC Q was used throughout the study period, limiting time bias. Patients assigned to HC Q group had moderate and severe illness at presentation, which would favor worse outcome with HC Q.
death, ↓51.3%, p=0.009
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.